ADVM Adverum Biotechnologies, Inc. Stock Quote

ADVM [NASD]

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	0.30%	Shs Outstand	97.60M	Perf Week	-2.42%
Market Cap	919.31M	Forward P/E	-	EPS next Y	-2.00	Insider Trans	9.14%	Shs Float	96.74M	Perf Month	-17.66%
Income	-117.50M	PEG	-	EPS next Q	-0.37	Inst Own	97.60%	Short Float	11.75%	Perf Quarter	-25.89%
Sales	-	P/S	-	EPS this Y	-37.20%	Inst Trans	-0.34%	Short Ratio	13.93	Perf Half Y	-25.30%
Book/sh	4.45	P/B	1.99	EPS next Y	-19.00%	ROA	-28.10%	Target Price	-	Perf Year	-23.75%
Cash/sh	4.14	P/C	2.14	EPS next 5Y	-	ROE	-31.60%	52W Range	8.75 - 26.98	Perf YTD	-18.27%
Dividend	-	P/FCF	-	EPS past 5Y	5.80%	ROI	-	52W High	-67.16%	Beta	1.41
Dividend %	-	Quick Ratio	20.80	Sales past 5Y	-	Gross Margin	-	52W Low	1.26%	ATR	0.63
Employees	167	Current Ratio	20.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.31	Volatility	5.57% 6.79%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-32.70%	Profit Margin	-	Rel Volume	1.32	Prev Close	9.40
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 01 AMC	Payout	-	Avg Volume	815.56K	Price	8.86
Recom	2.10	SMA20	-9.43%	SMA50	-22.09%	SMA200	-31.82%	Volume	1,075,277	Change	-5.74%

Dec-16-20

Initiated

UBS

Neutral

$13

Nov-12-20

Upgrade

Raymond James

Underperform → Mkt Perform

Jun-26-20

Downgrade

Raymond James

Mkt Perform → Underperform

May-13-20

Initiated

RBC Capital Mkts

Outperform

$24

May-05-20

Upgrade

SunTrust

Hold → Buy

$13 → $21

Apr-28-20

Initiated

Goldman

Buy

$17

Mar-16-20

Initiated

SVB Leerink

Outperform

$17

Feb-10-20

Upgrade

Chardan Capital Markets

Neutral → Buy

$20

Feb-10-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$8 → $21

Oct-15-19

Reiterated

Chardan Capital Markets

Neutral

$6 → $10

Sep-13-19

Reiterated

Chardan Capital Markets

Neutral

$10 → $6

Jun-14-19

Resumed

Raymond James

Mkt Perform

Nov-02-18

Downgrade

SunTrust

Buy → Hold

Nov-02-18

Downgrade

Raymond James

Outperform → Mkt Perform

Sep-21-18

Initiated

Cantor Fitzgerald

Overweight

Aug-30-18

Initiated

SunTrust

Buy

$11

Feb-15-18

Resumed

Piper Jaffray

Overweight

$12

Oct-12-17

Initiated

Raymond James

Outperform

Apr-16-21 08:05AM	Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 GlobeNewswire -5.74%
Apr-15-21 08:00AM	Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022 GlobeNewswire
Apr-08-21 09:39AM	The Sonic Fund II, L.P. Files Preliminary Proxy Statement Relating to the Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc. PR Newswire
Mar-30-21 09:00AM	Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials GlobeNewswire
Mar-18-21 04:00PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:16AM	The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga
Mar-17-21 05:10PM	Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation GlobeNewswire
Mar-05-21 08:30AM	Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock? Zacks
Mar-02-21 07:31AM	Adverum Biotechnologies, Inc. (ADVM) Q4 2020 Earnings Call Transcript Motley Fool -8.78%
Mar-01-21 05:25PM	Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:00PM	Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results GlobeNewswire
02:30PM	Adverum Biotechnologies, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 04:00PM	Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results GlobeNewswire
09:00AM	Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors GlobeNewswire
Feb-18-21 04:00PM	Adverum Appoints Christopher J. DeRespino as Chief Business Officer GlobeNewswire
Feb-10-21 04:49PM	Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting GlobeNewswire
Feb-02-21 09:00AM	Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy GlobeNewswire +7.29%
Jan-21-21 11:02PM	Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares Simply Wall St.
Jan-11-21 12:00PM	All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy Zacks
08:00AM	Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook GlobeNewswire
Jan-08-21 08:49AM	Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock Options Zacks
Jan-07-21 11:57AM	Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility GlobeNewswire
Jan-05-21 09:00AM	Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-20 10:23AM	Is ADVM A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-14-20 09:00AM	Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors GlobeNewswire +8.19%
Nov-23-20 11:00AM	Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference GlobeNewswire +7.46%
Nov-14-20 10:00AM	Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire
Nov-08-20 07:32AM	We're Hopeful That Adverum Biotechnologies (NASDAQ:ADVM) Will Use Its Cash Wisely Simply Wall St.
Nov-05-20 06:35PM	Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates Zacks -6.60%
04:01PM	Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results GlobeNewswire
Oct-20-20 09:00AM	Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual GlobeNewswire
Oct-09-20 08:56AM	Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock? Zacks
Sep-29-20 05:23PM	Adverum Biotechnologies, Inc. (ADVM) Is Stalling With Hedge Funds Insider Monkey
Sep-15-20 08:00AM	Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science GlobeNewswire
Sep-10-20 08:00AM	Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-08-20 08:57AM	New Strong Sell Stocks for September 8th Zacks
Aug-20-20 07:57AM	Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Increased Their Holdings Simply Wall St.
Aug-18-20 09:00AM	Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock GlobeNewswire
Aug-17-20 08:51AM	Adverum (ADVM) Surges: Stock Moves 6.2% Higher Zacks
Aug-12-20 09:37PM	Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock GlobeNewswire
Aug-11-20 04:01PM	Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock GlobeNewswire -16.63%
01:30PM	Adverum Biotechnologies, Inc. (ADVM) Q2 2020 Earnings Call Transcript Motley Fool
Aug-10-20 05:35PM	Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:00PM	Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results GlobeNewswire
Jul-29-20 04:05PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Jul-21-20 08:00AM	Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy GlobeNewswire
Jul-20-20 11:07AM	Did Hedge Funds Make The Right Call On Adverum Biotechnologies, Inc. (ADVM) ? Insider Monkey
Jul-13-20 08:30AM	Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME) GlobeNewswire -8.05%
Jul-06-20 09:00AM	Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD GlobeNewswire
Jun-30-20 11:50PM	Edited Transcript of ADVM earnings conference call or presentation 28-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-25-20 04:01PM	Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing GlobeNewswire
Jun-16-20 08:13AM	The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO Benzinga
Jun-15-20 04:01PM	Adverum Biotechnologies Announces Leadership Transition GlobeNewswire +11.22%
09:18AM	Hedge Funds Are Betting On Adverum Biotechnologies, Inc. (ADVM) Insider Monkey
Jun-04-20 04:05PM	Adverum Biotechnologies to Participate in Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-29-20 11:30AM	Adverum Biotechnologies, Inc. (ADVM) Q1 2020 Earnings Call Transcript Motley Fool
May-28-20 05:45PM	Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results GlobeNewswire
02:30PM	Adverum Biotechnologies, Inc. to Host Earnings Call ACCESSWIRE
May-25-20 11:30AM	Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? Zacks
May-21-20 04:05PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
May-09-20 08:00AM	3 Best Healthcare Stocks to Buy in May Motley Fool
May-07-20 11:30AM	Is Adverum Biotechnologies (ADVM) Outperforming Other Medical Stocks This Year? Zacks
May-06-20 12:53PM	Here's Why Adverum Biotechnologies Is Soaring Today Motley Fool +7.66%
May-05-20 04:11PM	Small Biotech Rockets To 5-Year High On Regeneron-Rivaling Gene Therapy Investor's Business Daily +38.35%
10:42AM	Why Adverum Biotechnologies Stock Is Soaring Today Motley Fool
08:00AM	The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout Benzinga
May-04-20 05:10PM	Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire +14.42%
08:20AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30% (NEWS-PORTAL) TipRanks
May-03-20 07:00AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30% TipRanks
Apr-30-20 04:05PM	Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO GlobeNewswire -9.26%
Apr-28-20 12:00PM	Here's Why Momentum Investors Will Love Adverum Biotechnologies (ADVM) Zacks
12:00PM	All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy Zacks
Apr-27-20 04:01PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD GlobeNewswire
08:00AM	Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire
Apr-20-20 04:05PM	Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors GlobeNewswire +8.91%
Apr-01-20 01:42AM	Edited Transcript of ADVM earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -10.54%
Mar-26-20 08:55AM	Adverum (ADVM): Strong Industry, Solid Earnings Estimate Revisions Zacks +9.21%
Mar-18-20 12:00PM	What Makes Adverum Biotechnologies (ADVM) a New Buy Stock Zacks -5.82%
Mar-16-20 06:06AM	Adverum Biotechnologies, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St. -13.17%
Mar-12-20 05:55PM	Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates Zacks -13.82%
04:01PM	Adverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results GlobeNewswire
02:30PM	Adverum Biotechnologies, Inc. to Host Earnings Call ACCESSWIRE
Mar-11-20 04:38PM	Adverum Biotechnologies Announces Data Presentations at ARVO 2020 GlobeNewswire -9.30%
09:46AM	Why Earnings Season Could Be Great for Adverum (ADVM) Zacks
Mar-05-20 04:01PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Mar-04-20 04:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. ADVM GlobeNewswire
Mar-03-20 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM ACCESSWIRE
10:29AM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. and Encourages Investors to Contact the Firm ACCESSWIRE
Mar-02-20 05:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM PR Newswire +6.74%
Feb-26-20 06:50PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. PR Newswire
12:30PM	Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline Zacks
09:30AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
Feb-25-20 03:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM ACCESSWIRE
12:26PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:00AM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. GlobeNewswire
08:00AM	Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer GlobeNewswire
Feb-24-20 05:31PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire -7.34%
05:10PM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. ACCESSWIRE

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fischer Laurent	CEO and Director	Mar 24	Buy	9.88	10,000	98,780	26,292	Mar 24 07:47 PM
Machado Patrick	Director	Mar 24	Buy	9.92	10,000	99,196	88,182	Mar 24 07:46 PM
PATTERSON LEONE D	President and CFO	Feb 09	Sale	14.10	12,533	176,718	97,955	Feb 11 07:47 PM
Machado Patrick	Director	Jan 15	Buy	11.52	10,000	115,174	78,182	Jan 19 08:33 PM
Fischer Laurent	CEO and Director	Jan 15	Buy	11.53	8,600	99,191	16,292	Jan 19 08:32 PM
Soparkar Peter	Chief Legal Officer	Aug 17	Buy	13.00	7,692	99,996	10,692	Aug 19 06:48 PM
Fischer Laurent	CEO and Director	Aug 17	Buy	13.00	7,692	99,996	7,692	Aug 19 06:45 PM
Gasmi Mehdi	Director	Jul 20	Option Exercise	4.80	5,000	24,000	279,442	Jul 22 09:44 PM
Gasmi Mehdi	Director	Jul 20	Sale	17.60	5,000	87,978	274,442	Jul 22 09:44 PM
Gasmi Mehdi	Director	Jun 22	Option Exercise	4.80	23,605	113,304	298,047	Jun 23 06:58 PM
Gasmi Mehdi	Director	Jun 22	Sale	25.06	23,605	591,617	274,442	Jun 23 06:58 PM
Gasmi Mehdi	Director	Jun 18	Option Exercise	4.80	11,127	53,410	285,569	Jun 18 09:45 PM
Gasmi Mehdi	Director	Jun 18	Sale	25.01	11,127	278,329	274,442	Jun 18 09:45 PM
Gasmi Mehdi	Director	Jun 17	Option Exercise	4.80	268	1,286	274,710	Jun 18 09:45 PM
Gasmi Mehdi	Director	Jun 17	Sale	25.01	268	6,703	274,442	Jun 18 09:45 PM
PATTERSON LEONE D	President	Jun 16	Sale	24.68	13,171	325,060	110,488	Jun 17 05:47 PM
Gasmi Mehdi	Director	Jun 15	Option Exercise	4.80	10,000	48,000	284,442	Jun 17 05:14 PM
Gasmi Mehdi	Director	Jun 15	Sale	21.86	10,000	218,627	274,442	Jun 17 05:14 PM
Gasmi Mehdi	Director	May 21	Option Exercise	4.80	3,599	17,275	278,041	May 22 06:55 PM
Gasmi Mehdi	Director	May 20	Option Exercise	4.80	1,401	6,725	275,843	May 22 06:55 PM
Gasmi Mehdi	Director	May 20	Sale	20.01	1,401	28,030	274,442	May 22 06:55 PM
Gasmi Mehdi	Director	May 18	Option Exercise	4.80	5,000	24,000	279,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 18	Sale	18.17	5,000	90,833	274,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 06	Option Exercise	4.80	25,000	120,000	299,442	May 20 07:34 PM
PATTERSON LEONE D	CEO, President and Director	May 06	Option Exercise	3.44	20,000	68,800	143,659	May 08 06:25 PM
Gasmi Mehdi	Director	May 06	Sale	20.03	25,000	500,668	274,442	May 20 07:34 PM
PATTERSON LEONE D	CEO, President and Director	May 06	Sale	20.02	20,000	400,400	123,659	May 08 06:25 PM
Gasmi Mehdi	Director	May 05	Option Exercise	4.80	10,000	48,000	284,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 05	Sale	16.26	10,000	162,573	274,442	May 20 07:34 PM
Scopa James Paul	Director	May 04	Option Exercise	6.48	23,334	151,204	53,334	May 05 06:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience